Sarah Siederer

1.0k citations

20 papers · 713 indexed · 1 hit paper · h-index 9

Infectious Diseases top 5%
Pulmonary and Respiratory Medicine top 10%
Physiology
Neurology top 10%
Cardiology and Cardiovascular Medicine

Co-authors: Rodger Kempsford Andrew I. Bayliffe William Powley Aili L. Lazaar Germain Poirier Brian Zeno Virginia Norris Kelly Hardes
Topics: Asthma and respiratory diseases (7 papers)Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers)Respiratory and Cough-Related Research (3 papers)
Cited by: Infectious Diseases Neurology Pulmonary and Respiratory Medicine
Journals: Critical Care Clinical Pharmacokinetics British Journal of Clinical Pharmacology
Partner nations: United Kingdom United States Australia

In The Last Decade

Sarah Siederer

20 papers receiving 700 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

2017 452 citations Akram Khan, Brian Zeno et al. Critical Care profile →

Peers

Countries citing papers authored by Sarah Siederer

Since Specialization

Citations

This map shows the geographic impact of Sarah Siederer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Siederer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Siederer more than expected).

Fields of papers citing papers by Sarah Siederer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Siederer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Siederer. The network helps show where Sarah Siederer may publish in the future.

Co-authorship network of co-authors of Sarah Siederer

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Siederer. A scholar is included among the top collaborators of Sarah Siederer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Siederer. Sarah Siederer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants 2024 ·Clinical and Translational Science ·(unknown),(unknown),(unknown),Jagtar Singh Nijjar,(unknown),(unknown),Sarah Siederer,(unknown),Edward C. Emery,(unknown),Geert Jan Groeneveld	2
2	Exploring the role of ex vivo metabolism on blood and plasma measurements of oxytocin among women in the third stage of labour: A post hoc study 2023 ·British Journal of Clinical Pharmacology ·Victoria Oliver,Sarah Siederer,Anthony Cahn,Katarzyna Gajewska‐Knapik,Rachel A. Gibson,(unknown),Carl M. J. Kirkpatrick,(unknown),Tri‐Hung Nguyen,Ian Schneider,(unknown),Michelle P. McIntosh,Simon Parry	3
3	OP0075 EFFICACY, SAFETY, PHARMACOKINETICS AND IMMUNOGENICITY OF REPEATED DOSING OF GSK3858279 IN PATIENTS WITH KNEE OSTEOARTHRITIS: A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2023 ·Jagtar Singh Nijjar,(unknown),(unknown),(unknown),(unknown),(unknown),Sarah Siederer,(unknown),Debra C. Bass,(unknown),Edward C. Emery	2
4	Pharmacokinetics and safety of inhaled oxytocin compared with intramuscular oxytocin in women in the third stage of labour: A randomized open‐label study 2023 ·British Journal of Clinical Pharmacology ·Katarzyna Gajewska‐Knapik,(unknown),(unknown),Kirsten R. Palmer,Anthony Cahn,Rachel A. Gibson,Carl M. J. Kirkpatrick,Simon Parry,Ian Schneider,Sarah Siederer,Annie Stylianou,Kimberley Hacquoil,Marcy Powell,(unknown),Michelle P. McIntosh,(unknown)	5
5	Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study 2021 ·Pulmonary Therapy ·David A. Hall,(unknown),Philipp Badorrek,Dominik Berliner,David C. Budd,(unknown),William Powley,(unknown),Sarah Siederer,Aili L. Lazaar,Anthony Cahn,Jens M. Hohlfeld	4
6	An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension 2021 ·Pulmonary Circulation ·Marc A. Simon,(unknown),David C. Budd,Ferràn Torres,Ekkehard Grünig,Pilar Escribano Subías,Manuel López‐Meseguer,Michael Halank,Christian Opitz,David A. Hall,(unknown),William Powley,Sarah Siederer,Andrew I. Bayliffe,Aili L. Lazaar,Anthony Cahn,Stephan Rosenkranz	11
7	Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor 2019 ·Toby M. Maher,Juliet K. Simpson,(unknown),Robert Chan,(unknown),Yi Cui,Sarah Siederer,Simon Parry,Julia Kenny,Robert J. Slack,Richard P. Marshall,Jagdeep Sahota,Gaia Rizzo,Graham E. Searle,Frederick J. Wilson,Azeem Saleem,Arthur R Kang’ombe,David Fairman,William A. Fahy,(unknown)	2
8	Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study 2017 ·EBioMedicine ·Disala Fernando,Sarah Siederer,(unknown),Ian Schneider,Ashutosh Gupta,Marcy Powell,Duncan Richards,Michelle P. McIntosh,(unknown),Susan Fowles	20
9	Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough 2017 ·International Journal of Clinical Pharmacology and Therapeutics ·John A. Smith,Lorcan McGarvey,Huda Badri,Imran Satia,(unknown),Sarah Siederer,Lia Liefaard,Robert Murdoch,(unknown),Joanna Marks-Kończalik	32
10	A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromebreakdown → 2017 ·Critical Care ·Akram Khan,(unknown),Brian Zeno,Timothy E. Albertson,John H. Boyd,Jason D. Christie,Richard Hall,Germain Poirier,Juan J. Ronco,Mark Tidswell,Kelly Hardes,William Powley,Tracey J. Wright,Sarah Siederer,David Fairman,David A. Lipson,Andrew I. Bayliffe,Aili L. Lazaar	452
11	Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma 2016 ·International Journal of Clinical Pharmacology and Therapeutics ·Ann Allen,Sarah Siederer,Shuying Yang	2
12	Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease 2015 ·European Journal of Drug Metabolism and Pharmacokinetics ·Sarah Siederer,Ann Allen,Shuying Yang	9
13	Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD 2012 ·Pulmonary Pharmacology & Therapeutics ·Rodger Kempsford,Virginia Norris,Sarah Siederer	60
14	Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans 2012 ·Drug Metabolism and Disposition ·Andrew W. Harrell,Sarah Siederer,(unknown),(unknown),Graeme Young,(unknown),(unknown),Andy D. Roberts,Claire Beaumont,Amanda Emmons,Adrian Pereira,Rodger Kempsford	45
15	Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study 2012 ·Clinical Therapeutics ·Joseph Boscia,(unknown),Michael T. Zvarich,Lisa Sanford,Sarah Siederer,Courtney Crim	39
16	Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man 2011 ·(unknown),Sarah Siederer,(unknown),Rodger Kempsford	2
17	GW642444, a Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist (LABA), At Single Doses Of 25, 50 And 100mcg, Is Well Tolerated And Demonstrates Prolonged Bronchodilation In Asthmatic Patients 2010 ·Rodger Kempsford,Virginia Norris,Sarah Siederer	2
18	The Pharmacodynamics, Pharmacokinetics And Tolerability Of Repeat Doses Of The Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist (LABA) GW642444 (25, 50 And 100mcg) In Healthy Subjects 2010 ·Rodger Kempsford,Virginia Norris,Sarah Siederer	3
19	GW642444, a Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist (LABA), At Single Doses Of 25, 50 And 100mcg, Is Well Tolerated And Demonstrates Prolonged Bronchodilation In COPD Patients 2010 ·Rodger Kempsford,Virginia Norris,Sarah Siederer	11
20	Clinical Pharmacology of Cilomilast 2006 ·Clinical Pharmacokinetics ·(unknown),Sarah Siederer,(unknown),Peter T. Daley‐Yates	7

About Sarah Siederer

Sarah Siederer is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Nephrology, having authored 20 papers that have together received 713 indexed citations. Recurring topics across this work include Asthma and respiratory diseases (7 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers) and Respiratory and Cough-Related Research (3 papers). The work is most often cited by research in Infectious Diseases (354 citations), Neurology (115 citations) and Pulmonary and Respiratory Medicine (230 citations). Sarah Siederer has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Rodger Kempsford, Andrew I. Bayliffe, William Powley, Aili L. Lazaar, Germain Poirier, Brian Zeno, Virginia Norris, Kelly Hardes, Akram Khan and David Fairman. Their work appears in journals such as Critical Care, Clinical Pharmacokinetics and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact